Medicenna Therapeutics in AI answers

Data as of Sep 19, 2026 · Based on 3,321,027 AI responses across 10,525 prompts · See how Parse measures this

Medicenna Therapeuticsmedicenna.com · Low evidence

Low evidence

Medicenna is a clinical-stage immunotherapy company that engineers interleukins to precisely modulate the immune system for cancer and other immune-driven diseases. Using directed evolution and AI-driven design, they re-engineer native interleukins and apply three platforms—Superkine, BiSKIT, and T-MASK—to tailor potency, selectivity, and tissue targeting. Their pipeline includes MDNA11 (IL-2-based super agonist), MDNA113 (anti-PD-1-IL-2 masked BiSKIT), and MDNA209/MDNA413, with collaborations including Merck and Fondazione Melanoma Onlus and active Phase 1/2 trials.

Parse Score

Questions where AI mentions Medicenna Therapeutics

Question	Visibility for this question
Which platform uses AI synthetic control arms to shrink trial control groups?	5.0

Medicenna Therapeuticsmedicenna.com · Low evidence

Low evidence

Parse Score